Trial Profile
Phase II Comparison Study of Hemostatic Efficacy of Escalating Doses of Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Oprelvekin (Primary)
- Indications Von Willebrand disease
- Focus Therapeutic Use
- 12 Jul 2014 New trial record